Vasomotor symptoms, such as daytime hot flashes and nighttime awakenings due to hot flashes, are commonly associated with menopausal women. The aim of this study was to assess desvenlafaxine in moderate to severe hot flashes in postmenopausal women. Electronic databases were searched for relevant randomized controlled trials that compared desvenlafaxine to placebo for postmenopausal women affected with hot flashes. The main outcomes were mean differences (MD) or standardized mean differences (SMD) and 95% confidence interval (CI) for change of the hot flashes. Six randomized controlled trials were identified in the meta-analysis. Pooled change of moderate and severe hot flashes frequency reduced SMD of -0.49 (95% CI -0.91 to -0.07) in desvenlafaxine 100 mg and -0.36 (95% CI -0.54 to -0.19) in desvenlafaxine 150 mg at week 12. Desvenlafaxine 100 mg reduced moderate and severe hot flashes frequency SMD of -0.74 (95% CI -1.05 to -0.44) within 26 weeks. There is no evidence for an increased risk of cardiovascular, cerebrovascular, or hepatic events associated with desvenlafaxine 100 mg/day. The meta-analysis suggests that treatment with desvenlafaxine 100 mg/day is associated with a significant reduction of moderate to severe hot flashes in postmenopausal women. Desvenlafaxine appears both safe and effective for treating hot flushes for up to 12 months.

Keywords:
Desvenlafaxine, Hot flashes, Adverse events, Meta-analysis
1.
Freedman RR, Norton D, Woodward S, Cornélissen G: Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995;80:2354-2358.
2.
Bachmann GA: Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180:S312-S316.
3.
Ziaei S, Kazemnejad A, Zareai M: The effect of vitamin E on hot flashes in menopausal women. Gynecol Obstet Invest 2007;64:204-207.
4.
Politi MC, Schleinitz MD, Col NF: Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med 2008;23:1507-1513.
5.
Igarashi M, Saito H, Morioka Y, et al: Stress vulnerability and climacteric symptoms: life events, coping behavior, and severity of symptoms. Gynecol Obstet Invest 2000;49:170-178.
6.
North American Menopause Society: Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242-255.
7.
Maclennan AH, Broadbent JL, Lester S, Moore V: Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;4:CD002978.
8.
Nelson HD: Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004;291:1610-1620.
9.
Lobo RA, McCormick W, Singer F, Roy S: Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol 1984;63:1-5.
10.
Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
11.
Wyrwich KW, Spratt DI, Gass M, et al: Identifying meaningful differences in vasomotor symptoms among menopausal women. Menopause 2008;15:698-705.
12.
Archer DF, Dupont CM, Constantine GD, et al: Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009;200:238 e1-238, e10.
13.
Archer DF, Seidman L, Constantine GD, et al: A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200:172 e1-e10.
14.
Gallagher JC, Strzinek RA, Cheng RF, et al: The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause. J Womens Health (Larchmt) 2012;21:188-198.
15.
Pinkerton JV, Constantine G, Hwang E, et al: Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause 2013;20:28-37.
16.
Cheng RJ, Dupont C, Archer DF, et al: Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms. Climacteric 2013;16:17-27.
17.
Pinkerton JV, Archer DF, Guico-Pabia CJ, et al: Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial. Menopause 2013;20:38-46.
18.
Archer DF, Pinkerton JV, Guico-Pabia CJ, et al: Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause. Menopause 2013;20:47-56.
19.
Bouchard P, Panay N, de Villiers TJ, et al: Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric 2012;15:12-20.
20.
Greene JG: Constructing a standard climacteric scale. Maturitas 1998;29:25-31.
21.
Higgins JPT, Green S: The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. 2009.
22.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
23.
Lau J, Ioannidis JP, Terrin N, et al: The case of the misleading funnel plot. BMJ 2006;333:597-600.
24.
Speroff L, Gass M, Constantine G, et al: Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77-87.
25.
Pinkerton JV, Constantine G, Hwang E, et al: Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause 2013;20:28-37.
26.
European Medicines Agency EMEA: Withdrawal assessment report for Pristiqs. Available at: http://wwwemeaeuropaeu/humandocs/PDFs/EPAR/pristiqs/H-794-WARpdf (accessed 02.09.08).
27.
Sproule BA, Hazra M, Pollock BG: Desvenlafaxine succinate for major depressive disorder. Drugs Today (Barc) 2008;44:475-487.
28.
Umland EM, Falconieri L: Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine. Int J Womens Health 2012;4:305-319.
29.
Deecher DC, Dorries K: Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health 2007;10:247-257.
30.
Simo A, Stevens RE, Ayres SA, Phelps KV: Perimenopausal women in estrogen vasomotor trials: contribution to placebo effect and efficacy outcome. Climacteric 2001;4:19-27.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.